Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2716)	1/29/2001 4:45:25 PM
From: Jibacoa	Respond to of 52153

IDEC: Profits much better: Idec Pharmaceuticals said after the close of trading Monday that fourth-quarter profit climbed to $20.4 million, or 12 cents per share, from $7.7 million, or 5 cents per share, in the year-ago fourth quarter. Idec's earnings were in line with the average estimate of analysts polled by First Call/Thomson Financial. Idec (IDPH) said revenue rose to $45.8 million from $32 million in the same period in 1999. Ahead of the report, shares gained $3.50 to $66.81.

To: Jibacoa who wrote (2716)	1/29/2001 4:55:36 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

SQNM: Some of the latest news: MENLO PARK, Calif., Jan. 26 /PRNewswire/ -- Protogene Laboratories, Inc. today announced a collaborative agreement with SEQUENOM(TM), Inc. (Nasdaq: SQNM - news) aimed at developing novel single nucleotide polymorphism (SNP) analysis tools suitable for use with SEQUENOM's MassARRAY system in genomics research and diagnostics. The collaboration will integrate proprietary surface tension DNA microarray technology developed by Protogene with SEQUENOM's MassARRAY system to enhance high-throughput SNP analysis on a silicon chip format. SNPs are among the most prevalent forms of genetic variation. Scientists analyze SNPs to discover linkages between disease and genes, and to generate information for accelerated drug development. Protogene has developed a way to quickly manufacture custom DNA microarrays that combines in situ synthesis of oligonucleotides with inkjet printing methods and patented surface tension array technology. The combination of these three technologies enables the manufacture of high quality microarrays. Protogene's technology for the in situ synthesis of oligonucleotides separated by differential surface tension is protected by a broad intellectual property portfolio that dates back to 1991. SEQUENOM's MassARRAY system enables large-scale SNP analysis by combining proprietary enzymology, bioinformatics and a miniaturized silicon chip-based format with the proven technology of mass spectrometry. The MassARRAY system analyzes molecules directly, without the need for labels or tags. This produces highly accurate and specific results that SEQUENOM expects will comply with future demands of clinical diagnostics. ``We are continually looking for products that enhance market possibilities for our MassARRAY system,'' said Toni Schuh, Ph.D., SEQUENOM's President and CEO. ``Protogene has a highly versatile technology for producing DNA microarrays that are easily customizable to the unique needs of our MassARRAY customers. This technology has the potential to accelerate the development of new applications for our MassARRAY system, including future generations of our SpectroCHIP(TM).'' ``We are very excited about collaborating with SEQUENOM to jointly develop high quality silicon-based SNP detection assays suitable for use in clinical diagnostics, as the opportunity to provide gene-based diagnostics for a wide variety of diseases may represent an emerging market opportunity of enormous potential,'' said Christopher R. Wolf, president and CEO of Protogene. ``At the same time, Protogene is actively pursuing additional partnerships for applications of our technology in markets offering high economic opportunity where the application of silicon-based microarrays could enable significant advances.'' SEQUENOM is a pioneer in the genomic era of large-scale genetic variation analysis. The Company provides technologies and information to identify the medical utility of genes and genetic variations, or SNPs, for developing diagnostic and therapeutic applications. SEQUENOM's SNP analysis products include the MassARRAY system, an automated SNP assay development process, a portfolio of over 400,000 SNP assays and a proprietary DNA bank. The unique data quality of the MassARRAY system enables rapid and high precision SNP allele frequency determination by analyzing hundreds of DNA samples simultaneously. The MassARRAY system is also capable of performing full genome screens, the analysis of a disease association of many SNPs across virtually all genes in the human genome and in many individuals. SEQUENOM is headquartered in San Diego, California with offices in Hamburg, Germany and Boston, Massachusetts. Protogene Laboratories, Inc., based in Menlo Park, California, is a developer and marketer of high-quality, fully customizable microarrays for life sciences research. Protogene's mission is to empower the individual researcher by making easy the rapid design and delivery of microarrays tailored to a user's own needs. Protogene's microarrays are intended to be completely compatible with other leading genomics tools already found in the researcher's lab, thereby avoiding unnecessary capital expenditures and other restrictions to widespread access. The privately held company was founded in November 1995 and currently has 90 employees. Information about Protogene is available on the Web at www.Protogene.com or by phoning: 650-289-2900.

To: Jibacoa who wrote (2716)	1/29/2001 8:00:10 PM
From: aknahow	Read Replies (3) \| Respond to of 52153

Any information, pro or con on Onyx Pharmaceutical (onxx) would be appreciated. I am specifically interested in what anyone know about the drug discussed in todays release. <<<"Onyx Pharmaceuticals is engaged in the discovery and development of novel targeted, highly selective cancer therapies. Based on its proprietary virus technologies, the company is developing CI-1042 as its lead product. CI-1042 is a therapeutic>>>" Never heard of Onyx before today. The drug is being developed with Pfizer and is in P III. tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and lyse (burst) cancer cells that have abnormal p53 pathway function while sparing normal cells that have functioning p53. Derangements in the p53 protein pathway are the most common genetic abnormalities in human cancer. CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of additional cancer indications.